REG - Immupharma PLC - New intellectual property strategy initiated

ImmuPharmaAnnouncement

02/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB9109Ia&default-theme=true

RNS Number : 9109I  Immupharma PLC  02 April 2024

 

02 April 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

New intellectual property strategy initiated

to significantly enhance patent life and commercial value for P140 technology
platform

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is pleased to announce that it has initiated a new intellectual
property strategy to significantly enhance the patent life and commercial
value for its P140 technology platform.

P140 is ImmuPharma's technology platform for its portfolio in autoimmune
diseases. This comprises the lead indication commencing a Phase 3 clinical
study in systemic lupus erythematosus ("SLE") and the second indication, in
preparation for a Phase 2/3 adaptive clinical study in chronic idiopathic
demyelinating polyneuropathy ("CIDP").

New insights into the P140 technology lends itself to expanding the current
patent portfolio. This new patent initiative will strengthen the commercial
value of P140 and add to the positive engagement we are already experiencing
in discussions with a broad range of potential commercial partners on SLE and
CIDP.

New patents will not only significantly enhance the patent protection for P140
in SLE and CIDP but will also support patient studies in other
auto-immune/inflammatory diseases and release further value from the P140
technology platform.

 

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:

 

"This is an important new initiative which will greatly improve the
intellectual property protection for our P140 technology platform and extend
its patent life significantly. This in turn creates greater shareholder value
and it is particularly pertinent as we progress discussions with a broad range
of potential commercial partners on both the SLE and CIDP programs."

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which many have side-effects and poor
response in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

 

About CIDP (Chronic Idiopathic Demyelinating Polyneuropathy)

 

CIDP is a rare acquired autoimmune disorder of peripheral nerves which is
thought to affect some 90,000individuals across US/Europe.  It is a rare
neurological disorder characterized by progressive weakness and impaired
sensory function in the legs and arms. CIDP related disability may be
substantial. In addition to the physical burdens imposed by the disease, those
affected by CIDP also frequently experience economic and emotional hardship
and are often burdened not only by the disease but also by the immunotherapies
used to treat the disease. Other than intravenous (IVIG) and subcutaneous
immunoglobulin (SCIG), corticosteroids and plasma exchange are the only other
treatment options. There is still a huge unmet need for more efficacious drugs
that are safer, and which affect underlying disease progression.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPURACUPCUAP